Compositions and methods for modulating factor viii function

Factor VIII variants with enhanced membrane binding properties address the limitations of current hemophilia A treatments by increasing coagulation activity and stability, enabling more effective and affordable therapies.

WO2026241400A1PCT designated stage Publication Date: 2026-11-19THE CHILDRENS HOSPITAL OF PHILADELPHIA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028013
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-14
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current treatments for hemophilia A, caused by deficiencies or dysfunctions in Factor VIII, are limited in efficacy and accessibility due to high costs and the need for improved FVIII molecules with enhanced biological properties.

Method used

Development of Factor VIII variants with specific amino acid substitutions, particularly at position 2251, to enhance binding to lipid membranes and platelets, along with methods for producing and administering these variants through gene therapy using vectors like AAV, to improve coagulation activity.

Benefits of technology

The Factor VIII variants demonstrate increased coagulation activity and stability, offering potential for more effective treatment of hemophilia A through improved hemostasis and reduced treatment costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026028013_19112026_PF_FP_ABST
    Figure US2026028013_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Factor VIII Variants comprising at least one substitution mutation at position 2251, compositions comprising the FVIII variants, nucleic acids and vectors encoding the FVIII variants, and methods of hemostasis related disorders using the FVIII variants are disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION

[0002] By

[0003] Lindsey A. George

[0004] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 63 / 805,489, filed May 14, 2025. The foregoing application is incorporated by reference herein.

[0005] FIELD OF THE INVENTION

[0006] The present invention relates to the fields of medicine and hematology. More specifically, the invention provides novel Factor VIII variants and methods of using the same to modulate the coagulation cascade in patients in need thereof.

[0007] BACKGROUND OF THE INVENTION

[0008] Several publications and patent documents are cited throughout the specification in order to describe the state of the art to which this invention pertains. Each of these citations is incorporated herein by reference as though set forth in full.

[0009] Coagulation factor VIII (FVIII) circulates in blood tightly bound to its carrier protein, von Willebrand factor (vWF) (Eaton, et al. (1986) Biochemistry 25(2):505-512; Vehar, et al. (1984) Nature 312(5992):337-342; Lollar, et al. (1988) J. Biol. Chem., 263(21): 10451-10455). Proteolytic processing by thrombin liberates FVIII from vWF and produces the active cofactor species (FVIIIa), which is a heterotrimer comprised of an A2-domain weakly associated with the metal ion-stabilized A1 / A3-C1-C2 heterodimer (Vehar, et al. (1984) Nature (1984) 312(5992):337-342; Fay, et al. (1992) J. Biol. Chem., 267(19): 13246-13250). Factor Villa associates with activated FIX (FIXa) on anionic phospholipid surfaces forming the intrinsic Xase enzyme complex, one of two enzymes that activates FX (Eaton, et al. (1986) Biochemistry 25(2):505-512; Hill-Eubanks, et al. (1990) J. Biol. Chem., 265(29): 17854-17858; Lenting, et al. (1994) J. Biol. Chem., 269(10):7150-7155; Venkateswarlu, D. (2014) Biochem. Biophys. Res. Comm., 452(3):408-414; Kolkman, et al. (1999) Biochem J., 339(Pt 2):217-221; Fay, et al. (1998) J. Biol. Chem., 273(30): 19049-19054; Kolkman, et al. (1999) 274(41):29087-29093; Kolkman, et al. (2000) Biochemistry 39(25):7398-7405). Deficiency or dysfunction of FVIII results in hemophilia A (HA), highlighting the importance of FVIIIa cofactor function. Downregulation of intrinsic Xase function is achieved through inhibition ofFIXa by antithrombin and possibly protein S (PS), and F Villa inactivation by spontaneous A2-domain dissociation or proteolytic cleavage at Arg336 and Arg562 by activated protein C (APC) (Lollar, et al. (1991) J. Biol. Chem., 266(19): 12481-12486; Hultin, et al. (1981) Blood 57(3):476-482; Lollar, et al. (1984) Blood 63(6): 1303-1308; Lollar, et al. (1990) J. Biol. Chem., 265(3): 1688-1692; Walker, et al. (1987) Arch.

[0010] Biochem. Biophys., 252(l):322-328; Plautz, et al. (2018) Arterioscler. Thromb. Vase. Biol., 38(4):816-828; Fay, et al. (1991) J. Biol. Chem., 266(30):20139-20145). Because FVIIIa has such a profound effect (103-106-fold) on increasing FIXa function, its inactivation is important for regulating intrinsic Xase function (van Dieijen, et al. (1981) J. Biol. Chem., 256(7):3433-3442; Mertens, et al. (1984) Biochem. J., 223(3):599-605).

[0011] Mutations in Factor VIII (FVIII) can lead to severe bleeding disorders and are associated with hemophilia A. Defective FVIII or a lack of FVIII activity results in an inability to effectively form clots. To date, only 20% of patients with hemophilia A worldwide receive regular treatment with FVIII replacement therapy due its high cost. Typically, FVIII therapy is plasma-derived or recombinantly produced. Gene therapy for hemophilia A based on AAV vectors is promising. Generating enhanced function FVIII variants would benefit the treatment of hemophilia. Therefore, there is an obvious need for FVIII molecules with improved biological properties.

[0012] SUMMARY OF THE INVENTION

[0013] In accordance with the present invention, compositions and methods for the modulation of hemostasis in patients in need thereof are provided. More specifically, Factor VIII (FVIII) variants which modulate (e.g., increase) hemostasis or blood coagulation are provided. In certain embodiments, the Factor VIII variant binds lipid membranes, phospholipid membranes, and / or platelets (e.g., activated or pro-coagulant platelets) better than wild-type FVIII (e.g., with greater affinity). In certain embodiments, the Factor VIII variant comprises a substitution mutation within the C2 domain, particularly within the membrane binding spikes such as at position 2251. In certain embodiments, the Leu at position 2251 is substituted with a non-leucine amino acid. In certain embodiments, the Leu at position 2251 is substituted with a non-hydrophobic amino acid. In certain embodiments, the Leu at position 2251 is substituted with a charged amino acid, particularly a positively charged amino acid. In certain embodiments, the Leu at position 2251 is substituted with His, Arg, or Lys.

[0014] Compositions comprising at least one FVIII variant of the instant invention and at leastone carrier (e.g., pharmaceutically acceptable carrier) are also provided. Nucleic acid molecules encoding the FVIII variants of the invention, including vectors such as viral vectors, are also disclosed as are methods of use thereof. Another aspect of the invention includes host cells expressing the FVIII variants described herein. Methods for isolating and purifying the FVIII variants are also disclosed.

[0015] Pharmaceutical compositions comprising the FVIII variants and / or FVIII variant encoding nucleic acid molecules of the invention in a carrier (e.g., pharmaceutically acceptable carrier) are also provided. The invention also includes gene therapy methods. The invention also includes methods for the treatment of a hemostasis related disorder in a subject or patient in need thereof or for the promotion or increase of blood coagulation in a subject or patient in need thereof comprising administration of a therapeutically effective amount of the FVIII variant and / or FVIII variant encoding nucleic acid molecules, particularly within a pharmaceutical composition. Such methods have efficacy in the treatment of disorders where a pro-coagulant is needed and include, without limitation, hemophilia, particularly hemophilia A.

[0016] In accordance with another aspect of the instant invention, compositions and methods for treating a subject with a truncated Factor VIII, particularly a FVIII 22 intron inversion, are provided.

[0017] BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 provides an amino acid sequence of FVIII (SEQ ID NO: 1). The amino acid at position 2251 is bolded and underlined. The B domain is also indicated with italics and bolding. The provided amino acid sequence lacks the 19 amino acid signal peptide at the N-terminus (MQIELSTCFFLCLLRFCFS (SEQ ID NO: 2)).

[0019] Figure 2 provides a graph of FVIII specific activity for the indicated FVIII variants (L2251 - WT). Data presented are mean ± SEM.

[0020] Figure 3 provides a graph showing the fold change of the indicated FVIII variants (L2251 - WT). Data presented are mean ± SEM.

[0021] Figure 4A provides a schematic of the FVIII intron 22 inversion mutation. In this intrachromosomal recombination event, intron 22 of FVIII recombines with one of two areas of homology upstream and telomeric of the FVIII sequence. This rearrangement splits FVIII into two parts, separating exons 1-22 from exons 23-26. The unaffected FVIII promoter continues to transcribe exons 1-22 exons, resulting in a truncated, nonfunctional protein. Figure 4B provides a graph showing the lead pegRNAcombinations insert attP into hF8 intron 22 with 20% efficiency in vitro. Data are mean ± SEM (n=2). Figure 4C provides a schematic showing eePASSIGE transfection with the lead pegRNA guide pair shows precise insertion.

[0022] DETAILED DESCRIPTION OF THE INVENTION Hemophilia A (HA) and hemophilia B (HB) are X-linked bleeding disorders due to inheritable deficiencies in either coagulation factor VIII (FVIII) or factor IX (FIX), respectively (Peyvandi, et al., Lancet (2016) 388:187-197; Konkle, et al., Hemophilia A in GeneReviews, Adam, et al., eds., University of Washington (1993)). The bleeding phenotype is generally related to the residual factor activity: people with severe disease (factor activity <1% normal) have frequent spontaneous bleeds; people with moderate disease (factor activity l%-5% normal) rarely have spontaneous bleeds, but bleed with minor trauma; and people with mild disease (factor activity 5%-40% normal) bleed during invasive procedures or trauma. Given this well-defined relationship between factor activity and bleeding phenotype, HA and HB are attractive targets for protein infusion or gene therapy as small increases in factor levels are expected to have a meaningful clinical impact.

[0023] As explained above, Factor VIII is central for coagulation activity and mutations in the FVIII gene result in hemophilia A, the most common form of hemophilia. Herein, specific changes in the amino acid sequence of FVIII are shown to be associated with increased activity and / or enhanced association with lipid membranes (e.g., activated platelets). Thus, the instant invention provides rationally designed amino acid residue modifications which provide unexpectedly superior variants.

[0024] Full-length FVIII is a large, 280-kDa protein primarily expressed in liver sinusoidal endothelial cells (LSECs), as well as extra-hepatic endothelial cells (Fahs, et al., Blood (2014) 123:3706-3713; Everett, et al., Blood (2014) 123:3697-3705). FVIII predominantly circulates as a heterodimer of a heavy chain and a light chain bound through noncovalent metal-dependent interactions (Lenting, et al., Blood (1998) 92:3983-3996). Factor VIII comprises several domains and is 2332 amino acids in length (mature without signal peptide). Generally, the domains are referred to as A1-A2-B-A3-C1-C2. FVIII is translated as a single-peptide chain (single chain) with the domain structure of Al-al-A2-a2-B-a3-A3-Cl-C2. Proteolytic cleavage of FVIII atR-1313 and / or R-1648 by the trans-Golgi protease furin results in heterodimer formation. The FVIII heavy chain (Al-al-A2-a2-B) and light chain (a3-A3-Cl-C2) remain associated through non-covalentmetal-ion-dependent interactions occurring between the Al and A3 domains. Initially, FVIII is in an inactive form bound to von Willebrand factor (vWF). FVIII is activated by cleavage by thrombin (Factor Ila) and release of the B domain. The activated form of FVIII (F Villa) separates from vWF and interacts with coagulation factor Factor IXa -leading to the formation of a blood clot via a coagulation cascade. During coagulation, FVIII single chain or heterodimer is activated to its heterotrimeric cofactor form by cleavage by thrombin at R-372, R-740, and R-1689. A2 remains associated with Al-al via non-covalent interactions. Inactivation of F Villa occurs via spontaneous A2 dissociation and / or proteolytic cleavage, primarily by activated protein C, at R-336 and R-562. FVIIIa is a cofactor for FIXa within the intrinsic Xase complex which functions to generate FXa, leading to the propagation of the coagulation cascade.

[0025] The B domain comprises 40% of the protein (908 amino acids) and is not required for the protein procoagulant activity (Brinkhous, et al., Proc. Natl. Acad. Sci. (1985) 82:8752-8756). The most common B-domain deleted (BDD) FVIII comprises 14 original amino acid residues (SFSQNPPVLKRHQR (SEQ ID NO: 3)) as a linker (Lind, et al. (1995) Eur. J. Biochem., 232(1): 19-27). This BDD FVIII is typically referred to as BDD-SQ or hFVIII-SQ. Short peptide linkers (e.g., 25 or fewer amino acids, 20 or fewer amino acids, 15 or fewer amino acids, or 10 or fewer amino acids - optionally derived directly from the B domain (e.g., beginning at the amino terminus of the B domain)) substituted for the B-domain can be used in FVIII variants (Lind, et al. (1995) Eur. J. Biochem., 232(1): 19-27; Pittman, et al., Blood (1993) 81:2925-2935; Toole, et al., Proc. Natl. Acad. Sci. (1986) 83:5939-5942). In a particular embodiment, the peptide linker comprises a basic amino acid (e.g., Arg, His, or Lys) at position -1 and -4 to Glul649. This BDD FVIII form is commonly used to produce recombinant BDD-FVIII (~ 4.4 Kb) as well for gene therapy (Bemtorp, E., Semin. Hematol. (2001) 38(2 Suppl 4): 1-3; Gouw, et al., N. Engl. J. Med. (2013) 368:231-239; Xi, et al., J. Thromb. Haemost. (2013) 11:1655-1662; Recht, et al., Haemophilia (2009) 15:869-880; Sabatino, et al., Mol. Ther. (2011) 19:442-449; Scallan, et al., Blood (2003) 102:2031-2037). As noted above, gene therapy using AAV vectors can only use shortened FVIII molecules such as a BDD-FVIII due to the limited packaging capacity of the AAV (4.7 Kb) and other vector systems (Lind, et al. (1995) Eur. J. Biochem., 232(1): 19-27). U.S. Patent 8,816,054, incorporated by reference herein, also provides BDD FVIII molecules with linkers of different lengths and sequences.In accordance with the instant invention, novel Factor VIII variants are provided. The instant invention encompasses FVIII variants including FVIIIa variants and FVIII prepeptide variants. For simplicity, the variants are generally described throughout the application in the context of FVIII. However, the invention contemplates and encompasses Factor FVIIIa and FVIII prepeptide molecules as well as Factor VIII domain(s) (e.g., C2 domain) with amino acid substitutions as described. In a particular embodiment, the FVIII variants are B-domain deleted (BDD) FVIII (optionally comprising a linker in place of the B-domain). In a particular embodiment, the FVIII variants comprise Al-al-A2-a2-B-a3-A3-Cl-C2. In a particular embodiment, the FVIII variants comprise Al-al-A2-a2-a3-A3-Cl-C2. In a particular embodiment, the FVIII variants comprise Al-al-A2-a2-A3-Cl-C2. In a particular embodiment, the FVIII variants comprise a light chain and a heavy chain.

[0026] As demonstrated herein, the FVIII variants of the instant invention unexpectedly possess greater activity compared to, e.g., wild-type FVIII.

[0027] The FVIII variants of the instant invention can be from any mammalian species. In a particular embodiment, the FVIII variant is human. Gene ID: 2157 and GenBank Accession Nos. NM_000132.3 and NP_000123.1 provide examples of the amino acid and nucleotide sequences of wild-type human FVIII (particularly the prepeptide comprising the signal peptide). GenBank NG 011403.2 also provides a gene sequence of FVIII on chromosome X and indicates the locations of exons and introns. Figure 1 provides SEQ ID NO: 1, which is an example of the amino acid sequence of human FVIII. SEQ ID NO: 1 lacks the 19 amino acid signal peptide at its N-terminus (MQIELSTCFFLCLLRFCFS (SEQ ID NO: 2)), although the FVIII variants of the instant invention may comprise the signal peptide. Nucleic acid molecules which encode Factor FVIII variants can be readily determined from the provided amino acid sequences as well as the provided GenBank Accession Nos.

[0028] The Factor VIII variants of the instant invention may comprise a mutation(s) which provides increased affinity for or binding to lipid membranes, such as phospholipid membranes. In certain embodiments, the Factor VIII variant has increased affinity for or binding to platelets, particularly activated or pro-coagulant platelets, compared to wildtype FVIII.

[0029] In certain embodiments, the Factor VIII variant comprises one or more substitution mutations in the C2 domain (e.g., amino acids 2172-2332). In certain embodiments, the Factor VIII variant comprises one or more substitution mutationswithin the membrane binding domains or spikes of the C2 domain. In certain embodiments, the Factor VIII variant comprises one or more substitution mutations at position L2251, L2252, M2199, and / or F2200. In certain embodiments, the Factor VIII variant comprises a substitution mutation at position L2251 and, optionally, one or more substitution mutations at positions L2252, M2199, and / or F2200. In certain embodiments, the Factor VIII variant comprises a substitution mutation at positions L2251 and L2252. In certain embodiments, the Factor VIII variant comprises a substitution mutation at position L2251 or L2252 and a substitution mutation at position M2199 or F2200. In certain embodiments, amino acid is substituted with a nonhydrophobic amino acid. In certain embodiments, the amino acid is substituted with a charged amino acid, particularly a positively charged amino acid. In certain embodiments, the amino acid is substituted with His, Arg, or Lys.

[0030] In certain embodiments, the Factor VIII variant comprises a substitution mutation at position 2251. In certain embodiments, the Leu at position 2251 is substituted with a non-leucine amino acid. In certain embodiments, the Leu at position 2251 is substituted with a non-hydrophobic amino acid. In certain embodiments, the Leu at position 2251 is substituted with a charged amino acid, particularly a positively charged amino acid. In certain embodiments, the Leu at position 2251 is substituted with His, Arg, or Lys.

[0031] In certain embodiments, the Factor VIII variant comprises a substitution mutation at position 2252. In certain embodiments, the Leu at position 2252 is substituted with a non-leucine amino acid. In certain embodiments, the Leu at position 2252 is substituted with a non-hydrophobic amino acid. In certain embodiments, the Leu at position 2252 is substituted with a charged amino acid, particularly a positively charged amino acid. In certain embodiments, the Leu at position 2252 is substituted with His, Arg, or Lys.

[0032] In certain embodiments, the Factor VIII variant comprises a substitution mutation at position 2200. In certain embodiments, the Phe at position 2200 is substituted with a non-phenylalanine amino acid. In certain embodiments, the Phe at position 2200 is substituted with a non-hydrophobic amino acid. In certain embodiments, the Phe at position 2200 is substituted with a charged amino acid, particularly a positively charged amino acid. In certain embodiments, the Phe at position 2200 is substituted with His, Arg, or Lys.

[0033] In certain embodiments, the Factor VIII variant comprises a substitution mutation at position 2199. In certain embodiments, the Met at position 2199 is substituted with a non-methionine amino acid. In certain embodiments, the Met at position 2199 issubstituted with a non-hydrophobic amino acid. In certain embodiments, the Met at position 2199 is substituted with a charged amino acid, particularly a positively charged amino acid. In certain embodiments, the Met at position 2199 is substituted with His, Arg, or Lys.

[0034] As stated hereinabove, the FVIII variant of the instant invention may be human. In a particular embodiment, the FVIII variant of the instant invention has at least 75%, 80%, 85%, 90%, 95%, 97%, 99%, or 100% homology (identity) with SEQ ID NO: 1 (or fragment or domain thereof or an activated FVIII fragment thereof), particularly at least 90%, 95%, 97%, 99%, or 100% homology (identity). In a particular embodiment, the FVIII variant comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 97%, 99%, or 100% homology (identity), particularly at least 90%, 95%, 97%, 99%, or 100% homology (identity), with amino acids 1-740 of SEQ ID NO: 1 (or fragment or domain thereof or an activated FVIII fragment thereof) and an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 97%, 99%, or 100% homology (identity), particularly at least 90%, 95%, 97%, 99%, or 100% homology (identity) with amino acids 1649-2332 or 1690-2332 of SEQ ID NO: 1 (or fragment or domain thereof or an activated FVIII fragment thereof). The homology (identity) percentages above exclude the substitution mutations set forth herein.

[0035] The FVIII variants of the instant invention may also be post-translationally modified. The FVIII variants may be post-translationally modified in a cell (particularly a human cell) or in vitro.

[0036] Nucleic acid molecules encoding the above FVIII variants (or fragments or domains thereof or activated fragments thereof) are also encompassed by the instant invention. Nucleic acid molecules encoding the variants may be prepared by any method known in the art. The nucleic acid molecules may be maintained in any convenient vector, particularly an expression vector. In certain embodiments, the nucleic acid molecule encompasses only exons 23-26 of FVIII. In certain embodiments, the nucleic acid molecule comprises exons 23-26 of FVIII, but lacks exons 1-22. In certain embodiments, the nucleic acid molecule which comprises exons 23-26 of FVIII can either further comprise introns or lack the introns between exons 23-26. In certain embodiments, the nucleic acid molecule comprising exons 23-26 of FVIII is less than about 1000 nucleotides, less than about 900 nucleotides, less than about 800 nucleotides, less than about 700 nucleotides, or less than about 650 nucleotides. In certain embodiments, the exons and / or introns are as presented in GenBank NG 011403.2 orencode the same amino acid sequence as presented in GenBank NG 011403.2 or SEQ ID NO: 1. An example sequence of exon 23 is: gtct tctttggcaa tgtggattca tctgggataa aacacaatat ttttaaccct ccaattattg ctcgatacat ccgtttgcac ccaactcatt atagcattcg cagcactctt cgcatggagt tgatgggctg tgatttaaat a (SEQ ID NO: 4). An example sequence of exon 24 is: gtt gcagcatgcc attgggaatg gagagtaaag caatatcaga tgcacagatt actgcttcat cctactttac caatatgttt gccacctggt ctccttcaaa agctcgactt cacctccaag ggaggagtaa tgcctggaga cctcag (SEQ ID NO: 5). An example sequence of exon 25 is: gtgaa taatccaaaa gagtggctgc aagtggactt ccagaagaca atgaaagtca caggagtaac tactcaggga gtaaaatctc tgcttaccag catgtatgtg aaggagttcc tcatctccag cagtcaagat ggccatcagt ggactctctt ttttcagaat ggcaaagtaa ag (SEQ ID NO: 6). An example sequence of exon 26 is: gtttttcag ggaaatcaag actccttcac acctgtggtg aactctctag acccaccgtt actgactcgc taccttcgaa ttcaccccca gagttgggtg caccagattg ccctgaggat ggaggttctg ggctgcgagg cacaggacct ctactgaggg tggccactgc agcacctgcc actgccgtca cctctccctc ctcagctcca gggcagtgtc cctccctggc ttgccttcta cctttgtgct aaatcctagc agacactgcc ttgaagcctc ctgaattaac tatcatcagt cctgcatttc tttggtgggg ggccaggagg gtgcatccaa tttaacttaa ctcttaccta ttttctgcag ctgctcccag attactcctt ccttccaata taactaggca aaaagaagtg aggagaaacc tgcatgaaag cattcttccc tgaaaagtta ggcctctcag agtcaccact tcctctgttg tagaaaaact atgtgatgaa actttgaaaa agatatttat gatgttaaca tttcaggtta agcctcatac gtttaaaata aaactctcag ttgtttatta tcctgatcaa gcatggaaca aagcatgttt caggatcaga tcaatacaat cttggagtca aaaggcaaat catttggaca atctgcaaaa tggagagaat acaataacta ctacagtaaa gtctgtttct gcttccttac acatagatat aattatgtta tttagtcatt atgaggggca cattcttatc tccaaaacta gcattcttaa actgagaatt atagatgggg ttcaagaatc cctaagtccc ctgaaattat ataaggcatt ctgtataaat gcaaatgtgc atttttctga cgagtgtcca tagatataaa gccatttggt cttaattctg accaataaaa aaataagtca ggaggatgca attgttgaaa gctttgaaat aaaataacaa tgtcttcttg aaatttgtga tggccaagaa agaaaatgat gatgacatta ggcttctaaa ggacatacat ttaatatttc tgtggaaata tgaggaaaat ccatggttat ctgagatagg agatacaaac tttgtaattc taataatgca ctcagtttac tctctccctc tactaatttc ctgctgaaaa taacacaaca aaaatgtaac aggggaaatt atataccgtg actgaaaact agagtcctac ttacatagtt gaaatatcaa ggaggtcaga agaaaattgg actggtgaaa acagaaaaaa cactccagtc tgccatatca ccacacaata ggatccccct tcttgccctc cacccccata agattgtgaa gggtttactg ctccttccat ctgcctgacc ccttcactat gactacacag aatctcctga tagtaaaggg ggctggagac aaggataagt tatagagcag ttggaggaag catccaaaga ttgcaaccca gggcaaatgg aaaacaggag atcctaatat gaaagaaaaa tggatcccaa tctgagaaaa ggcaaaagaa tggctacttt tttctatgct ggagtatttt ctaataatcc tgcttgaccc ttatctgacc tctttggaaa ctataacata gctgtcacag tatagtcaca atccacaaat gatgcaggtg caaatggttt atagccctgt gaagttctta aagtttagag gctaacttac agaaatgaat aagttgtttt gttttatagc ccggtagagg agttaacccc aaaggtgata tggttttatt tcctgttatg tttaacttga taatcttatt ttggcattct tttcccattg actatataca tctctatttc tcaaatgttc atggaactag ctcttttatt ttcctgctgg tttcttcagt aatgagttaa ataaaacatt gacacataca aa(SEQ ID NO: 7) or, particularly, gtttttcag ggaaatcaag actccttcac acctgtggtg aactctctag acccaccgtt actgactcgc taccttcgaa ttcaccccca gagttgggtg caccagattg ccctgaggat ggaggttctg ggctgcgagg cacaggacct ctactga (SEQ ID NO: 8). In certain embodiments, the nucleic acid molecule comprises SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 8 (e.g., from 5’ to 3’).

[0037] Compositions comprising at least one FVIII variant and at least one carrier (e.g., pharmaceutically acceptable carrier) are also encompassed by the instant invention. In a particular embodiment, the FVIII is isolated and / or substantially pure within the composition. Compositions comprising at least one FVIII variant nucleic acid molecule and at least one carrier (e.g., pharmaceutically acceptable carrier) are also encompassed by the instant invention. Except insofar as any conventional carrier is incompatible with the variant to be administered, its use in the pharmaceutical composition is contemplated. In a particular embodiment, the carrier is a pharmaceutically acceptable carrier for intravenous administration.

[0038] Nucleic acid molecules encoding the variants of the invention may be prepared by using recombinant DNA technology methods. The availability of nucleotide sequence information enables preparation of isolated nucleic acid molecules of the invention by a variety of means. For example, nucleic acid sequences encoding a variant may be isolated from appropriate biological sources using standard protocols well known in the art.

[0039] Nucleic acids of the present invention may be maintained as RNA or DNA in any convenient cloning vector. In a particular embodiment, clones are maintained in a plasmid cloning / expression vector, which is propagated in a suitable host cell (e.g., E. colt). Alternatively, the nucleic acids may be maintained in a vector suitable for expression in mammalian cells. In cases where post-translational modification affects variant function, it is preferable to express the molecule in mammalian cells, particularly human cells.

[0040] FVIII variant encoding nucleic acid molecules of the invention include DNA, cDNA, genomic DNA, RNA, and fragments thereof which may be single- or doublestranded. Thus, this invention provides oligonucleotides (sense or antisense strands of DNA or RNA) having sequences capable of hybridizing with at least one sequence of a nucleic acid molecule of the present invention. Such oligonucleotides are useful as probes for detecting variant expression.The FVIII variants of the present invention may be prepared in a variety of ways, according to known methods. The protein may be purified from appropriate sources (e.g., transformed bacterial or animal (e.g., mammalian or human) cultured cells or tissues which express FVIII variants), for example, by immunoaffinity purification or cation exchange chromatography purification. The availability of nucleic acid molecules encoding the variants enables production of the variants using in vitro expression methods known in the art. For example, a cDNA or gene may be cloned into an appropriate in vitro transcription vector followed by cell-free translation in a suitable cell-free translation system, such as wheat germ or rabbit reticulocyte lysates. In vitro transcription and translation systems are commercially available.

[0041] Alternatively, larger quantities of variant may be produced by expression in a suitable prokaryotic or eukaryotic expression system. For example, part or all of a DNA molecule encoding the FVIII variant may be inserted into a plasmid vector adapted for expression in a bacterial cell, such as E. coli, or a mammalian cell (particularly a human cell) such as CHO, BHK, or HeLa cells. Alternatively, tagged fusion proteins comprising the variant can be generated. Such variant-tagged fusion proteins are encoded by part or all of a DNA molecule, ligated in the correct codon reading frame to a nucleotide sequence encoding a portion or all of a desired polypeptide tag which is inserted into a plasmid vector adapted for expression in a bacterial cell, such as E. coli or a eukaryotic cell, such as, but not limited to, yeast and mammalian cells, particularly human cells. Vectors such as those described above comprise the regulatory elements necessary for expression of the DNA in the host cell positioned in such a manner as to permit expression of the DNA in the host cell. Such regulatory elements required for expression include, but are not limited to, promoter sequences, transcription initiation sequences, and enhancer sequences.

[0042] FVIII variant proteins, produced by gene expression in a recombinant prokaryotic or eukaryotic system (particularly human) may be purified according to methods known in the art. In a particular embodiment, a commercially available express! on / secretion system can be used, whereby the recombinant protein is expressed and thereafter secreted from the host cell, to be easily purified from the surrounding medium. If expression / secretion vectors are not used, an alternative approach involves purifying the recombinant protein by affinity separation, such as by immunological interaction with antibodies that bind specifically to the recombinant protein or nickel columns for isolation of recombinant proteins tagged with 6-8 histidine residues at their N-terminus or C-terminus. Alternative tags may comprise, without limitation, the FLAG epitope, GST or the hemagglutinin epitope. Such methods are commonly used by skilled practitioners.

[0043] FVIII variant proteins, prepared by the aforementioned methods, may be analyzed according to standard procedures. For example, such proteins may be subjected to amino acid sequence analysis, according to known methods.

[0044] As discussed above, a convenient way of producing a polypeptide according to the present invention is to express nucleic acid encoding it, by use of the nucleic acid in an expression system. A variety of expression systems of utility for the methods of the present invention are well known to those of skill in the art.

[0045] Accordingly, the present invention also encompasses a method of making a polypeptide. In certain embodiments, the method includes expression from nucleic acid encoding the polypeptide. This may conveniently be achieved by culturing a host cell, containing such a vector, under appropriate conditions which cause or allow production of the polypeptide. Polypeptides may also be produced in in vitro systems, such as in reticulocyte lysates.

[0046] FVIII variant proteins and nucleic acids of the instant invention may be used, for example, as therapeutic and / or prophylactic agents which modulate the blood coagulation cascade. The FVIII variant proteins and nucleic acids of the instant invention may be administered in a therapeutically effective amount to modulate (e.g., increase) hemostasis and / or form a clot and / or stop or inhibit bleeding or aberrant bleeding. It is demonstrated herein that the FVIII variants possess superior properties and can provide effective hemostasis.

[0047] In a particular embodiment of the present invention, FVIII variants may be administered to a patient via infusion in a biologically compatible carrier, e.g., via injection or intravenous injection. The FVIII variants of the invention may optionally be encapsulated into liposomes or mixed with other phospholipids or micelles to increase stability of the molecule. FVIII variants may be administered alone or in combination with other agents known to modulate hemostasis (e.g., vFW, Factor IX, Factor IXa, etc.). An appropriate composition in which to deliver the FVIII variant may be determined by a medical practitioner upon consideration of a variety of physiological variables, including, but not limited to, the patient’s condition and hemodynamic state. A variety of compositions well suited for different applications and routes of administration are well known in the art and are described hereinbelow.The preparation containing the FVIII variants may contain a physiologically acceptable matrix and is formulated as a pharmaceutical preparation. The preparation can be formulated using substantially known methods, it can be mixed with a buffer containing salts, such as NaCl, CaCh, and amino acids, such as glycine and / or lysine, and in a pH range from 6 to 8. Until needed, the purified preparation containing the FVIII variant can be stored in the form of a finished solution or in lyophilized or deep-frozen form. In a particular embodiment, the preparation is stored in lyophilized form and is dissolved into a visually clear solution using an appropriate reconstitution solution.

[0048] Alternatively, the preparation according to the present invention can also be made available as a liquid preparation or as a liquid that is deep-frozen. The preparation according to the present invention may be especially stable, i.e., it can be allowed to stand in dissolved form for a prolonged time prior to application.

[0049] The preparation according to the present invention can be made available as a pharmaceutical preparation with the FVIII variant in the form of a one-component preparation or in combination with other factors in the form of a multi-component preparation.

[0050] Prior to processing the purified protein into a pharmaceutical preparation, the purified protein may be subjected to the conventional quality controls and fashioned into a therapeutic form of presentation. In particular, during the recombinant manufacture, the purified preparation may be tested for the absence of cellular nucleic acids as well as nucleic acids that are derived from the expression vector.

[0051] Another feature of this invention relates to making available a preparation which contains a FVIII variant with a high stability and structural integrity and which, in particular, is free from inactive FVIII intermediates and / or proteolytic degradation products and and by formulating it into an appropriate preparation.

[0052] The pharmaceutical preparation may contain, as an example, dosages of between about 1-1000 pg / kg, about 10-500 pg / kg, about 10-250 pg / kg, or about 10-100 pg / kg. In a particular embodiment, the pharmaceutical protein preparation may comprise a dosage of 30-100 lU / kg (e.g., as a single daily injection or up to 3 times or more / day). Patients may be treated immediately upon presentation at the clinic with a bleed or prior to the delivery of cut / wound causing a bleed. Alternatively, patients may receive a bolus infusion every one to three, eight, or twelve hours or, if sufficient improvement is observed, a once daily infusion of the FVIII variant described herein.FVIII variant-encoding nucleic acids may be used for a variety of purposes in accordance with the present invention such as gene therapy and / or gene editing. In a particular embodiment of the invention, a nucleic acid delivery vehicle (e.g., an expression vector such as a viral vector) for modulating blood coagulation is provided wherein the expression vector comprises a nucleic acid sequence coding for a FVIII variant as described herein. Administration of the FVIII variant-encoding expression vectors to a patient results in the expression of the FVIII variant which serves to alter the coagulation cascade. In accordance with the present invention, a FVIII variant encoding nucleic acid sequence may encode a variant polypeptide as described herein whose expression increases hemostasis. In a particular embodiment, the nucleic acid sequence encodes a human FVIII variant.

[0053] Expression vectors comprising FVIII variant nucleic acid sequences may be administered alone, or in combination with other molecules useful for modulating hemostasis. According to the present invention, the expression vectors or combination of therapeutic agents may be administered to the patient alone or in a pharmaceutically acceptable or biologically compatible composition.

[0054] In a particular embodiment of the invention, the expression vector comprising nucleic acid sequences encoding the FVIII variant is a viral vector or non-viral vector. Viral vectors which may be used in the present invention include, but are not limited to, adenoviral vectors (with or without tissue specific promoters / enhancers), adeno-associated virus (AAV) vectors of any serotype (e.g., AAV-1 to AAV-12, particularly AAV-2, AAV-5, AAV-7, and AAV-8) and hybrid AAV vectors, lentivirus vectors and pseudo-typed lentivirus vectors (e.g., Ebola virus, vesicular stomatitis virus (VSV), and feline immunodeficiency virus (FIV)), herpes simplex virus vectors, vaccinia virus vectors, and retroviral vectors. Examples of non-viral means include, without limitation, gene delivery by lipid nanoparticles. In a particular embodiment, the vector is an adeno-associated virus (AAV) vector. In a particular embodiment, the vector is a lentiviral vector.

[0055] The instant invention also encompasses gene therapy methods (e.g., for modulating hemostasis) with the FVIII variants of the instant invention. In a particular embodiment of the present invention, methods are provided for the administration of a viral vector comprising nucleic acid sequences encoding a FVIII variant. Viral (e.g., AAV) vectors of utility in the methods of the present invention preferably include at least the essential parts of viral (e.g., AAV) vector DNA. As described herein, expression of aFVIII variant following administration of such a viral (e.g., AAV) vector serves to modulate hemostasis, particularly to enhance the procoagulation activity of the protease.

[0056] Recombinant viral (e.g., AAV) vectors have found broad utility for a variety of gene therapy applications. Their utility for such applications is due largely to the high efficiency of in vivo gene transfer achieved in a variety of organ contexts.

[0057] AAV particles may be used to advantage as vehicles for adequate gene delivery. Such virions possess a number of desirable features for such applications, including: structural features related to being a double stranded DNA nonenveloped virus and biological features such as a tropism for the human respiratory system and gastrointestinal tract. Moreover, AAV are known to infect a wide variety of cell types in vivo and in vitro by receptor-mediated endocytosis. Attesting to the overall safety of AAV vectors, infection with AAV leads to a minimal disease state in humans comprising mild flu-like symptoms.

[0058] Viral (e.g., AAV) genomes are well suited for use as gene therapy vehicles because they can accommodate the insertion of foreign DNA following the removal of viral genes essential for replication and / or nonessential regions. Such substitutions render the viral vector impaired with regard to replicative functions and infectivity. Many viruses (e.g., AAV) have been used as vectors for gene therapy and for expression of heterologous genes.

[0059] It is desirable to introduce a vector that can provide, for example, multiple copies of a desired gene and hence greater amounts of the product of that gene. Improved viral (e.g., AAV) vectors and methods for producing these vectors have been described (e.g., Penn Vector Core; addgene; etc.).

[0060] For some applications, an expression construct may further comprise regulatory elements which serve to drive expression in a particular cell or tissue type and / or constitutively. Such regulatory elements are known to those of skill in the art. The incorporation of tissue specific regulatory elements in the expression constructs of the present invention provides for at least partial tissue tropism for the expression of the variant or functional fragments thereof. In certain embodiments, a constitutive promoter (e.g., cytomegalovirus (CMV) promoter) may be used. Hematopoietic or liver specific promoters may also be used.

[0061] AAV for recombinant gene expression have been produced in human cells (e.g., the human embryonic kidney cell line 293). Briefly, AAV vectors are typically engineered from wild-type AAV, a single-stranded DNA virus that is non-pathogenic.The parent virus is non-pathogenic, the vectors have a broad host range, and they can infect both dividing and non-dividing cells. The vector is typically engineered from the virus by deleting the rep and cap genes and replacing these with the transgene of interest under the control of a specific promoter. For recombinant AAV preparation, the upper size limit of the sequence that can be inserted between the two ITRs is about 4.7 kb. Plasmids expressing a FVIII variant under the control of a promoter (e.g., the CMV promoter / enhancer) and a second plasmid supplying adenovirus helper functions along with a third plasmid containing the rep and cap genes (e.g., AAV-2 rep and cap genes) may be used to produce AAV vectors (e.g., AAV-2 vectors). Other AAV serotype cap genes (e.g., AAV-1, AAV-6, or AAV-8 cap genes) may be expressed with other serotype rep genes and ITRs (e.g., AAV-2 rep gene and ITRs) to produce different vectors (e.g., Gao et al. (2002) Proc. Natl. Acad. Sci. USA 99:11854-11859; Xiao et al., (1999) J. Virol. 73:3994-4003; Arruda et al., (2004) Blood 103:85-92). AAV vectors may be purified by repeated CsCl density gradient centrifugation and the titer of purified vectors determined by quantitative dot-blot hybridization. In a particular embodiment, vectors may be prepared by the Vector Core at The Children's Hospital of Philadelphia.

[0062] Also included in the present invention is a method for modulating hemostasis comprising providing cells of an individual with a nucleic acid delivery vehicle encoding a FVIII variant and allowing the cells to grow under conditions wherein the FVIII variant is expressed.

[0063] From the foregoing discussion, it can be seen that FVIII variants and FVIII variant encoding nucleic acid molecules (e.g., FVIII variant expressing nucleic acid vectors) may be used in the treatment of disorders associated with aberrant blood coagulation. The instant invention encompasses methods of increasing FVIII activity (e.g., by introducing at least a substitution mutation at position 2251 as described herein). The FVIII variants of the instant invention have demonstrated increased activity compared to wild-type FVIII.

[0064] FVIII variant encoding nucleic acid molecules (e.g., expression vectors) of the present invention may be incorporated into pharmaceutical compositions that may be delivered to a subject, so as to allow production of a biologically active protein (e.g., a FVIII variant) or by inducing expression of the FVIII variant in vivo by gene- and or cellbased therapies or by ex vivo modification / transduction of the patient's or donor's cells. The FVIII variant encoding nucleic acid molecules may be used for gene addition or gene editing to express the FVIII variants of the instant invention. In a particular embodimentof the present invention, pharmaceutical compositions comprising sufficient genetic material to enable a recipient to produce a therapeutically effective amount of a FVIII variant can influence hemostasis in the subject. Alternatively, as discussed above, an effective amount of the FVIII variant may be directly infused into a patient in need thereof. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents (e.g., co-factors) which influence hemostasis.

[0065] In particular embodiments, the compositions (e.g., pharmaceutical compositions) of the instant invention also contain a pharmaceutically acceptable carrier. Such carriers include any pharmaceutical agent that does not itself induce an immune response harmful to the individual receiving the composition, and which may be administered without undue toxicity. Pharmaceutically acceptable carriers include, but are not limited to, liquids such as water, saline, glycerol, sugars and ethanol. Pharmaceutically acceptable salts can also be included therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences.

[0066] Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

[0067] The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonicsolvents than are the corresponding, free base forms. In other cases, the preparation may be a lyophilized powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

[0068] After pharmaceutical compositions have been prepared, they may be placed in an appropriate container and labeled for treatment. For administration of FVIII variants or FVIII variant encoding nucleic acids (e.g., vectors), such labeling could include amount, frequency, and method of administration.

[0069] Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended therapeutic purpose. Determining a therapeutically effective dose is well within the capability of a skilled medical practitioner using the techniques and guidance provided in the present invention. Therapeutic doses will depend on, among other factors, the age and general condition of the subject, the severity of the aberrant blood coagulation phenotype, and the strength of the control sequences regulating the expression levels of the variant polypeptide. Thus, a therapeutically effective amount in humans will fall in a relatively broad range that may be determined by a medical practitioner based on the response of an individual patient to vector-based variant treatment.

[0070] The FVIII variants, alone or in combination with other agents, may be directly infused into a patient in an appropriate biological / pharmaceutical carrier as described hereinabove. Expression vectors of the present invention comprising nucleic acid sequences encoding variant or functional fragments thereof, may be administered to a patient by a variety of means (see below) to achieve and maintain a prophylactically and / or therapeutically effective level of the variant polypeptide. One of skill in the art could readily determine specific protocols for using the variant encoding expression vectors of the present invention for the therapeutic treatment of a particular patient.

[0071] FVIII variants and / or FVIII variant encoding nucleic acids (e.g., AAV vectors) of the present invention may be administered to a patient by any means known. Direct delivery of the pharmaceutical compositions in vivo may generally be accomplished via injection using a conventional syringe, although other delivery methods such as convection-enhanced delivery are envisioned. In this regard, the compositions may be delivered subcutaneously, epidermally, intradermally, intrathecally, intraorbitally, intramucosally, intraperitoneally, intravenously, intraarterially, orally, intrahepatically orintramuscularly. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal applications. In certain embodiments, the FVIII is administered by injection (e.g., to the bloodstream). In certain embodiments, the FVIII variant encoding nucleic acids (e.g., AAV vectors) is administered by injection (e.g., to the bloodstream or liver). A clinician specializing in the treatment of patients with blood coagulation disorders may determine the optimal route for administration of the vectors (e.g., AAV vectors) comprising variant nucleic acid sequences based on a number of criteria, including, but not limited to: the condition of the patient and the purpose of the treatment (e.g., reduced blood coagulation).

[0072] The present invention also encompasses vectors (e.g., viral vectors or AAV vectors) comprising a nucleic acid sequence encoding a FVIII variant. Also provided are lentiviruses or pseudo-typed lentivirus vectors comprising a nucleic acid sequence encoding a FVIII variant. Also encompassed are naked plasmid or expression vectors comprising a nucleic acid sequence encoding a FVIII variant.

[0073] In accordance with another aspect of the instant invention, methods of treating a hemostasis related disorder, particularly hemophilia (e.g., hemophilia A, particularly severe hemophilia A), in a subject are provided. In certain embodiments, the subject has a FVIII intron 22 inversion or produces FVIII which lack the portion encoded by exons 23-26. In certain embodiments, the method comprises inserting (e.g., knocking in) a nucleic acid molecule comprising exons 23-26 of FVIII after (3’) exon 22 of FVIII in the genome and, optionally, before (5’) the recombination event that caused the FVIII intron 22 inversion. In certain embodiments, the nucleic acid molecule comprising exons 23-26 of FVIII encodes the FVIII variant of the instant invention (e.g., a substitution mutation at L2251). In certain embodiments, the nucleic acid molecule comprises SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 8. In certain embodiments, the nucleic acid molecule comprising exons 23-26 of FVIII is less than about 1000 nucleotides, less than about 900 nucleotides, less than about 800 nucleotides, less than about 700 nucleotides, or less than about 650 nucleotides in length.

[0074] In certain embodiments, the nucleic acid molecule comprising exons 23-26 of FVIII is inserted into the FVIII gene of the subject using any gene editing technology including, for example, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and PASSIGE. In certain embodiments, PASSIGE mor enhanced eePASSIGE is used. PASSIGE is prime-editing-assisted site-specific integrase gene editing.

[0075] PASSIGE uses prime editing and site-specific large serine recombinases (LSRs) tointegrate DNA into targeted sites in the genome, (e.g., mammalian genome). Briefly, PASSIGE utilizes single-flap or dual-flap prime editing to install a site-specific recombinase landing site into a target genomic location, wherein a recombinase catalyzes cargo DNA insertion into the landing site (Anzalone, et al. (2022) Nat. Biotechnol., 40:731-740; Anzalone, et al. (2019) Nature 576:149-157). In certain embodiments, eePASSIGE, which utilizes a Bxbl variant serine integrase (evoBxbl or eeBxbl), is used (Pandey et al. (2025) Nat. Biomed. Eng., 9:22-39). In certain embodiments, the PASSAGE utilizes prime editing RNA guides (pegRNAs) within the first 500 bp of intron 22 of F VIII. In certain embodiments, the attP sequence is inserted into the genome, e.g., via twin-prime editing. In certain embodiments, the guides are used with the prime editor (PE)6d variant. In certain embodiments, the donor DNA (e.g., a nucleic acid molecule comprising exons 23-26 of FVIII (e.g., SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 8)) comprises attB. In certain embodiments, the prime editor (e.g., PE6d), a serine integrase / recombinase (e.g., eeBxbl), pegRNAs (e.g., for inserting attp), and a nucleic acid molecule comprising exons 23-26 of FVIII, splice acceptor, and / or an attB sequence, are administered to the cell (e.g., nucleic acid molecules encoding certain of the components (e.g., proteins)). In certain embodiments, the components for gene editing (e.g., prime editing components) are contained in a lipid nanoparticle (LNP). In certain embodiments, the components for gene editing are delivered to the liver. In certain embodiments, the components for gene editing are delivered to liver sinusoidal endothelial cells (LSECs). In certain embodiments, the LNPs are targeted to the liver (e.g., comprise liver targeting moieties on their surface). In certain embodiments, the LNPs are targeted to LSECs (e.g., comprise LESC targeting moieties on their surface).

[0076] Definitions

[0077] The following definitions are provided to facilitate an understanding of the present invention.

[0078] The singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.

[0079] The phrase “hemostasis related disorder” refers to bleeding disorders such as, without limitation, hemophilia A, hemophilia B, hemophilia A and B patients, hemophilia with inhibitory antibodies, deficiencies in at least one coagulation factor (e.g., Factors VII, VIII, IX, X, XI, V, XII, II, and / or von Willebrand factor, particularly Factor VIII),combined FV / FVIII deficiency, vitamin K epoxide reductase Cl deficiency, gammacarboxylase deficiency, bleeding associated with trauma or injury, thrombosis, thrombocytopenia, stroke, coagulopathy (hypocoagulability), disseminated intravascular coagulation (DIC), over-anticoagulation associated with heparin, low molecular weight heparin, pentasaccharide, warfarin, or small molecule antithrombotics (e.g., FXa inhibitors); and platelet disorders such as, Bernard Soulier syndrome, Glanzman thromblastemia, and storage pool deficiency. In a particular embodiment, the term “hemostasis related disorder” refers to bleeding disorders characterized by excessive and / or uncontrolled bleeding (e.g., a disorder which can be treated with a procoagulant). In a particular embodiment, the hemostasis related disorder is hemophilia. In a particular embodiment, the hemostasis related disorder is hemophilia A.

[0080] With reference to nucleic acids of the invention, the term “isolated nucleic acid” is sometimes used. This term, when applied to DNA, refers to a DNA molecule that is separated from sequences with which it is immediately contiguous (in the 5' and 3' directions) in the naturally occurring genome of the organism from which it originates. For example, the “isolated nucleic acid” may comprise a DNA or cDNA molecule inserted into a vector, such as a plasmid or virus vector, or integrated into the DNA of a prokaryote or eukaryote. With respect to RNA molecules of the invention, the term “isolated nucleic acid” primarily refers to an RNA molecule encoded by an isolated DNA molecule as defined above. Alternatively, the term may refer to an RNA molecule that has been sufficiently separated from RNA molecules with which it would be associated in its natural state (i.e., in cells or tissues), such that it exists in a “substantially pure” form.

[0081] With respect to protein, the term “isolated protein” is sometimes used herein. This term may refer to a protein produced by expression of an isolated nucleic acid molecule of the invention. Alternatively, this term may refer to a protein which has been sufficiently separated from other proteins with which it would naturally be associated (e.g., so as to exist in “substantially pure” form). “Isolated” is not meant to exclude artificial or synthetic mixtures with other compounds or materials, or the presence of impurities that do not interfere with the fundamental activity, and that may be present, for example, due to incomplete purification, or the addition of stabilizers.

[0082] The term “vector” refers to a carrier nucleic acid molecule (e.g., RNA or DNA) into which a nucleic acid sequence can be inserted for introduction into a host cell where it will be replicated. An “expression vector” is a specialized vector that contains a geneor nucleic acid sequence with the necessary regulatory regions (e.g., promoter) needed for expression in a host cell.

[0083] The term “operably linked” means that the regulatory sequences necessary for expression of a coding sequence are placed in the DNA molecule in the appropriate positions relative to the coding sequence so as to effect expression of the coding sequence. This same definition is sometimes applied to the arrangement of coding sequences and transcription control elements (e.g. promoters, enhancers, and termination elements) in an expression vector. This definition is also sometimes applied to the arrangement of nucleic acid sequences of a first and a second nucleic acid molecule wherein a hybrid nucleic acid molecule is generated.

[0084] The term “substantially pure” refers to a preparation comprising at least 50-60% by weight the compound of interest (e.g., nucleic acid, oligonucleotide, protein, etc.), particularly at least 75% by weight, or at least 90-99% or more by weight of the compound of interest. Purity may be measured by methods appropriate for the compound of interest (e.g. chromatographic methods, agarose or polyacrylamide gel electrophoresis, HPLC analysis, and the like).

[0085] “Pharmaceutically acceptable” indicates approval by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.

[0086] A “carrier” refers to, for example, a diluent, adjuvant, preservative (e.g., Thimersol, benzyl alcohol), anti-oxidant (e.g., ascorbic acid, sodium metabisulfite), solubilizer (e.g., polysorbate 80), emulsifier, buffer (e.g., Tris HC1, acetate, phosphate), antimicrobial, bulking substance (e.g., lactose, mannitol), excipient, auxiliary agent or vehicle with which an active agent of the present invention is administered.

[0087] Pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin. Water or aqueous saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E.W. Martin (Mack Publishing Co., Easton, PA); Gennaro, A. R., Remington: The Science and Practice of Pharmacy, (Lippincott, Williams and Wilkins); Liberman, et al., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y.; and Kibbe, et al., Eds., Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Washington.As used herein, the term “subject” refers to an animal, particularly a mammal, particularly a human.

[0088] The term “treat” as used herein refers to any type of treatment that imparts a benefit to a patient afflicted with a disease, including improvement in the condition of the patient (e.g., in one or more symptoms), delay in the progression of the condition, etc.

[0089] As used herein, the term “prevent” refers to the prophylactic treatment of a subject who is at risk of developing a condition (e.g., aberrant bleeding) resulting in a decrease in the probability that the subject will develop the condition.

[0090] A “therapeutically effective amount” of a compound or a pharmaceutical composition refers to an amount effective to prevent, inhibit, treat, and / or lessen the symptoms of a particular disorder or disease.

[0091] The following examples are provided to illustrate various embodiments of the present invention. The examples are illustrative and are not intended to limit the invention in any way.

[0092] EXAMPLE 1

[0093] FVIII binds to activated platelets and acts as a cofactor for FIXa, which then activates Factor X, assisting in the coagulation process of clot formation. FVIII residue L2251 is important for the function of FVIII due to its role in phospholipid binding. Exons 23-26 of FVIII encode a portion of the Cl domain and the entirety of the C2 domain of FVIII. The C2 domain is primarily responsible for binding to phospholipid membranes, which is necessary for FVIIIa procoagulant effect. Residue L2251 of the C2 domain is highly conserved among species, suggesting its significance in FVIII function.

[0094] FVIII specific activity was determined for a series of L2251 variants. Briefly, Huh7 cells were transiently transfected with 2.5pg F8 variant plasmid DNA in a 6-well plate. 24 hours after transfection, the media was replaced with FBS-free media for accurate functional assessment in clotting assays. Three days after transfection, media was collected and FVIII activity was determined by an activated partial thromboplastin time (aPTT) assay. FVIII antigen values were determined by human FVIII ELISA. Data presented in Figure 2 are mean ± SEM. Figure 3 provides a graph showing the fold change of L2251 variants. Compared to WT L2251, variant L2251K has the highest foldchange of specific activity between tested residues. As seen in Table 1, L2251 variants with positively charged side chains have the highest fold change over WT.

[0095] Without being bound by theory, phospholipid heads have negatively charged phosphate groups that may bind better to amino acids with positively charged side chains. The fold change differences among positively charged amino acids could be a result of size differences (D.R. Lide, Handbook of Chemistry and Physics, 72nd Edition, CRC Press, Boca Raton, FL, 1991).

[0096] Amino Acid Side Chain Characteristic Molecular Weight (g / mol)

[0097] L2251 hydrophobic 131.18

[0098] L2251I hydrophobic 131.18

[0099] L2251F hydrophobic 165.19

[0100] L2251N polar 114.11

[0101] L2251H Positively charged 155.16

[0102] L2251R Positively charged 174.20

[0103]

[0104] L2251K Positively charged 146.19

[0105] 'able 1: Characteristics of F VIII variants

[0106] A rational approach to improve C2-domain phospholipid membrane binding provides enhanced FVIII function and permits greater therapeutic benefits.

[0107] EXAMPLE 2

[0108] Hemophilia A is the most common severe congenital bleeding disorder due to FVIII mutations resulting in deficient function of the coagulation FVIII protein. Given that modest FVIII function imparts large phenotypic improvement, even low-efficiency FVIII gene correction or integration can be clinically significant. The FVIII intron 22 inversion mutation accounts for nearly 50% of severe hemophilia A cases. In this intrachromosomal recombination event, a gene within intron 22 of FVIII recombines with one of two copies outside of the FVIII sequence, telomeric on the chromosome. This rearrangement splits FVIII into two parts, separating exons 1-22 from exons 23-26. The unaffected FVIII promoter continues to transcribe the first 22 exons, resulting in a truncated, nonfunctional protein (Fig. 4A).

[0109] Knock-in of exons 23-26 cDNA into intron 22, before the site of recombination, can rescue transcription of the full FVIII gene through the sustained use of the endogenous promoter to restore hemostatic function. Due to the size of exons 23-26 cDNA (627 bp), few tools are available for the insertion of a DNA fragment this sizewithout double-stranded breaks. Herein, it is demonstrated that the use of twin prime editing, PASSIGE, or any similar derivatives can correct the FVIII disease-causing mutation including the intron 22 inversion. More specifically, enhanced eePASSIGE (Pandey et al. (2025) Nat. Biomed. Eng., 9:22-39) is used to efficiently insert codon-optimized exons 23-26 cDNA using single-stranded breaks, minimizing genotoxicity risk, to rescue complete transcription of FVIII and restore FVIII hemostatic function. Knock-in of exons 23-26 cDNA (627 bp) into intron 22, before the site of recombination rescues complete FVIII transcription from the endogenous promoter to restore proper hemostatic function.

[0110] eePASSIGE uses the eeBxbl serine integrase to facilitate recombination between attP, which is inserted into the genome via twin-prime editing, and attB, which carries the donor DNA. Thus, eePASSIGE can be used to efficiently insert exons 23-26 cDNA using single-stranded breaks, thereby minimizing the risk of genotoxicity, to rescue complete transcription of FVIII and restore FVIII hemostatic function. Enhance donor cDNA to supplement editing through increased protein activity.

[0111] 63 combinations of prime editing RNA guides (pegRNAs) were designed in the first 500 bp of intron 22 of FVIII to insert the attP sequence. The guides were transfected in Huh7 cells with the prime editor (PE)6d variant. Screening results were analyzed through next-generation sequencing (NGS) to determine precise attP insertion, imperfect edits, and non-homologous end joining (NHEJ) indels. Five combinations of guides, varying only by primer binding site lengths, achieved >18% precise insertion with <1.4% imperfect edits and <0.3% NHEJ indels. NHEJ indel percentages were consistent with untransfected control cells and thus considered negative. Figure 4B shows the lead pegRNA combinations insert attP into hF8 intron 22 with 20% efficiency in vitro.

[0112] The highest achieving guide pair, which demonstrated 20.13% precise insertion, 1.27% imperfect edits, and 0.21% NHEJ indels, was used in the following transfection. PE6d, eeBxbl, pegRNAs, and a donor plasmid containing FVIII exons 23-26 cDNA, splice acceptor, and attB sequence, were co-transfected in Huh7 cells to assess integration of the donor. Insertion was evaluated by junction PCR of the region between endogenous intron 22 and the newly introduced exon 23. Sanger sequencing results showed recombination of attP and attB forming attL as well as the correct insertion and orientation of the splice acceptor and the FVIII exons 23-26 cDNA (Fig. 4C).

[0113] These data support the use of eePASSIGE to restore loss of FVIII function for hemophilia A patients with intron 22 inversion mutations through the insertion of exons23-26 cDNA with expression driven off the endogenous FVIII promoter. The use of single-stranded breaks provides improved safety over gene editing platforms that impart double-stranded breaks. Combining this approach with rationally improved C2-domain function (e.g., by substitution mutation at L2251 or other amino acid) indicate that even modest editing efficiency can impart significant phenotypic benefit. The correction of the FVIII intron 22 inversion can be further studied in a humanized FVIII intron 22 inversion mouse model.

[0114] While certain of the preferred embodiments of the present invention have been described and specifically exemplified above, it is not intended that the invention be limited to such embodiments. Various modifications may be made thereto without departing from the scope and spirit of the present invention, as set forth in the following claims.

Claims

WHAT IS CLAIMED IS1. A Factor VIII (FVIII) variant comprising a substitution mutation at position 2251.

2. The FVIII variant of claim 1, wherein the Leu at position 2251 is substituted with a non-hydrophobic amino acid.

3. The FVIII variant of claim 1, wherein the Leu at position 2251 is substituted with a positively charged amino acid.

4. The FVIII variant of claim 1, wherein the Leu at position 2251 is substituted with Lys.

5. The FVIII variant of claim 1, further comprising one or more substitution mutations at positions L2252, M2199, and / or F2200.

6. The FVIII variant of any one of claims 1-5, wherein the FVIII variant lacks the B domain or the B domain has been replaced by a peptide linker.

7. The FVIII variant of any one of claims 1-6, wherein said FVIII variant comprises amino acids 1-740 and 1649-2332 of SEQ ID NO: 1.

8. The FVIII variant of any one of claims 1-6, wherein said FVIII variant comprises amino acids 1-740 and 1690-2332 of SEQ ID NO: 1.

9. A composition comprising at least one FVIII variant of any one of claims 1-8 and at least one pharmaceutically acceptable carrier.

10. The activated form of the FVIII variant of any one of claims 1-8.

11. An isolated nucleic acid molecule encoding the FVIII variant of any one of claims 1-8.

12. The nucleic acid molecule of claim 11, wherein said FVIII variant comprises a signal peptide.

13. An expression vector comprising the nucleic acid molecule of claim 11 operably linked to a regulatory sequence.

14. The vector of claim 13, selected from the group consisting of an adenovirus-associated vector, a retroviral vector, a plasmid, and a lentiviral vector.

15. The vector of claim 13, which is an adenovirus-associated vector16. A host cell comprising the vector of claim 13.

17. The host cell of claim 16, wherein said host cells are human cells.

18. A composition comprising at least one nucleic acid molecule of any one of claims Ills and at least one pharmaceutically acceptable carrier.

19. A method for treatment of a hemostasis related disorder in a patient in need thereof comprising administering a therapeutically effective amount of the FVIII variant of any one of claims 1-8 or the nucleic acid molecule of any one of claims 11-15, optionally in a pharmaceutically acceptable carrier, to said patient.

20. The method of claim 19, wherein said hemostasis related disorder is hemophilia.

21. A method for reducing blood loss in a patient in need thereof comprising administering a therapeutically effective amount of the FVIII variant of any one of claims 1-8 or the nucleic acid molecule of any one of claims 11-15, optionally in a pharmaceutically acceptable carrier, to said patient.

22. A method for treating a subject with hemophilia A, wherein said subject has a FVIII intron 22 inversion, said method comprising inserting a nucleic acid molecule comprising exons 23-26 of FVIII after (3’) exon 22 of FVIII in the genome and, optionally, before (5’) the recombination event that caused the FVIII intron 22 inversion, wherein said exons 23-26 of FVIII comprise a substitution mutation at position 2251.

23. The method of claim 22, wherein the Leu at position 2251 is substituted with Lys.